
Are you a teenager with moderate to severe atopic dermatitis?
Amgen is conducting a Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of XXXXXXXXXXX in Adolescent Subjects With